• As U.S. research restrictions are lifted there is a rising interest in the use of plant-therapy in sports medicine
• Cannabis in sports medicine took center stage at the Tokyo Olympics
• American athletes are turning more and more to cannabis as a pain reliever, alternative to opioids, and part of an overall sports recovery plan

RYAH Group (CSE: RYAH) (formerly RYAH Medtech), the leader in dose-control technology for plant-based medicine, works with researchers to provide a full turnkey solution for clinical studies from start to finish. RYAH Group’s dose-control devices standardize the dosing protocol, QR products ensure compliance, and mobile apps collect the necessary data. As research restrictions throughout the U.S. lift, RYAH Group is standing by, ready to provide IoT hardware, software, and data analytics that reduce variations in patient-related clinical trials. One of the areas that the U.S. is poised to explore is cannabis in sports medicine. Cannabis in sports medicine is a controversial topic and is often not tolerated in professional and collegiate organizations. However, it’s also a topic that took center stage during this year’s Tokyo Olympics. The World Anti-Doping Agency (“WADA”) removing CBD as a prohibited substance in 2017 combined with the 2018 Farm Bill helped change the conversation around CBD use for athletes. As a result, American athletes are turning more and more to cannabis as a pain reliever, alternative to opioids, and part of a recovery plan. Megan Rapinoe is an advocate for the use of CBDs in sports recovery. She has incorporated it into her everyday recovery plan but was unable to continue while competing in Tokyo. Rapinoe shared that not being able to take the products she has been using to manage her pain, inflammation, mood, and sleep at the Olympics is “quite frustrating.” “We’re expected to perform on the biggest stages and highest levels, yet we can’t use all-natural products to help us recover,” stated Rapinoe (https://ibn.fm/ExEkd). “It’s not right, and these policies need to be changed to reflect where our culture is.” The NFL is leading the way forward in exploring the benefits of plant-therapy for players. The NFL and the NFL Players Association (“NFLPA”) announced on June 8, 2021, they are investing $1 million in funding for novel pain treatments that include cannabis and CBD therapy (https://ibn.fm/GiVM9). They will be providing five research grants to eligible applicants by November of 2021. From 2014 to 2020, the NFL had 801 injures and a 30 percent jump in reported concussions. The NFL is looking for alternatives to opioids, and it seeks out answers to the effectiveness, dosing requirements, and effect of the performance alterations of cannabis. Until now, there hasn’t been studies done regarding sports medicine directly. The NFLPA is changing this. Sports organizations across the U.S. must rethink their strict policies with the legalization of recreational and medicinal cannabis across the U.S. The good news is that with these new studies around plant therapy in sports medicine, a new era of pain management and recovery accepted by sports organizations worldwide may lie right around the corner for athletes like Rapinoe. RYAH Group is working alongside researchers globally, providing a holistic approach to therapeutic plant treatment and unlocking the data from seed to consumption. The company’s in-depth analytical reports help to identify significant trends, like the one in sports medicine, in plant therapy For more information, visit the company’s website at www.RYAHGroup.com. NOTE TO INVESTORS: The latest news and updates relating to RYAH are available in the company’s newsroom at https://ibn.fm/RYAH

• The company has the ability to rent out properties on Airbnb at scale
• reAlpha has raised more than $6 million in two funding rounds led by $1.3 billion real estate group Crawford Hoying
• As of July 2021, reAlpha is testing the waters on a Reg A public offering to raise $75 million
• The company plans to spend $1.5 billion to acquire short-term rental properties
• reAlpha’s use of technology and relationships with lending institutions allow it to analyze thousands of properties per minute and purchase hundreds of properties at a time
• reAlpha forecasts annual revenue of $434 million by 2025
• The total asset value of the global short-term rental property market is estimated at $1.2 trillion

reAlpha is the Robinhood of Airbnb investments, representing the intersection of modern technology and lasting assets. A new wave of investment opportunities in real estate has emerged, and Airbnb short-term rentals are changing hospitality and travel on a global scale. Previously, only accredited investors have had access to the best real estate deals, but reAlpha is democratizing this lucrative new model, empowering anyone to generate wealth as a reAlpha member. reAlpha uses its proprietary, disruptive technologies to level the playing field, unraveling the industry’s high barriers to entry and bringing the power of real estate investing to the “99 percent.” The company’s unique model allows investors to benefit from both the superior returns of short-term rental income and increases in property value through renovation and appreciating markets. reAlpha likens this double investment return to seeing two desserts on a dinner menu and ordering both. The company seeks to open up access to real estate investing by letting regular people buy fractional ownership of short-term rentals using reAlpha’s smartphone app. The reAlpha app simplifies the real estate investing process. In the app, investors can check out the company’s most current properties offered for investment. If they choose to invest, they become members of a syndicate invested in a specific short-term rental property. Syndicate members receive quarterly dividend payments from rental revenue generated by the property in which they invested. The reAlpha model merges the most historically stable asset – real estate – with technology and the sharing-economy business model of the future – Airbnb. The company handles all property management functions and believes short-term rentals are no longer purely transactional and occupancy-driven. reAlpha reimagines the entire guest experience end-to-end to make sure the reAlphaHouse is the ultimate on-demand rental property. The company plans to implement various technologies, including smart locks, voice-activated electronics, home automation systems, and innovative furnishings, to create an unparalleled guest experience. When guests have exceptional stays, investors enjoy maximized profits. How it Works reAlpha has identified specific markets in which to purchase short-term rentals across the globe. The company prefers to buy 100 to 500 properties in each market. reAlpha uses artificial intelligence technology, dubbed reAlphaBRAIN, to select “unicorn properties,” the best available opportunities in the market for investment. The AI software can quickly evaluate thousands of property listings based on 25+ factors and assign each a reAlphaScore, projecting how Airbnb Viable the property is, as well as its projected value in the housing market. For a minimum investment of $2,500, an investor can purchase equity in a specific reAlpha property, similar to how they would buy stock or shares in a company. reAlpha matches the investor with other like-minded backers to form a syndicate, so together they can cover a down payment on the selected property. Investment properties usually require a down payment of 25 percent of the purchase price, but, with reAlpha properties, the down payment is only 10 percent because of the company’s relationships with lenders, making the initial investment more affordable. reAlpha maintains a majority stake in each investment syndicate, retaining 51 percent ownership in each purchased property and ensuring their interests are always aligned with investing members. Properties are typically refinanced after 12 to 16 months, freeing equity for reinvestment in additional properties. The company uses its AI software to predict optimum timing to sell properties in order to extract maximum value for investors. Gains are reinvested in additional properties. However, reAlpha also believes that real estate investing is more than financial returns. It includes the pride of ownership and the freedom of financial security. reAlpha members have access to their property when it is not rented out on Airbnb. The company is driven every day to create not only lucrative returns for its members but also to deliver exceptional experiences and positive impact in the communities in which reAlpha lives and operates. Market Outlook There are an estimated 7.4 million short-term rental properties worldwide. The total asset value of this global market is projected at $1.2 trillion. In the U.S. there are about 1.8 million short-term rental properties. These have an estimated asset value of $933 billion. Brain Chesky, the CEO of Airbnb, recently stated that there is a shortage of properties to meet demand and that the company will need “millions of more hosts.” reAlpha is projecting that the company and its investors will own 5,000 short-term rental investment properties by 2025. reAlpha forecasts annual revenue of $434 million by 2025. Management Team Giri Devanur is the CEO and co-founder of reAlpha. Prior to founding reAlpha, he served as president and CEO of enterprise software company Ameri100 Inc. from its founding in 2013. He scaled Ameri100 from zero to $50 million in revenue and took the company public in 2017. That same year, he was named E&Y Entrepreneur of the Year. He immigrated to the U.S. with virtually no possessions and $65 in the bank. He earned a Master’s in Technology Management from Columbia University, where he continues to mentor aspiring entrepreneurs. Monaz Karkaria is the COO and co-founder of reAlpha. Prior to reAlpha, she founded real estate management firm Ben Zen Properties LLC. She has also worked in branch operations for Citibank. Before her involvement in Citibank, she worked at Berlitz in Sao Paulo, Brazil, as an ESL business coach and consultant for various international business clients like GE, Google, PepsiCo and others. She began her career in sales and marketing at Smith & Nephew Dubai. She is also a popular real estate coach and speaker. Mike Logozzo is the CFO of reAlpha. Prior to joining the company, he served as Managing Director, Americas for innovation advisory firm L Marks. Before that, he was General Manager, Financial Services Operations, Americas Region for BMW Group Financial Services, where he also held Special Projects Manager and CIC Strategy Manager positions. Christie Currie is the CMO of reAlpha. Previously, Christie launched her own business in the MedTech space, Zandaland, where she worked closely with large enterprises and health care systems. Currie’s work in the startup community led her to London-based corporate innovation firm L Marks, where she led world-leading corporations in retail, supply chain and logistics, and health care to identify strategic areas of need and successfully engage industry-disrupting startups. Currie has mentored hundreds of these startups, helping them to align their technology solutions with market needs. For more information, visit the company’s website at www.reAlpha.com. NOTE TO INVESTORS: The latest news and updates relating to reAlpha are available in the company’s newsroom at https://ibn.fm/reAlpha

• FingerMotion recently announced it has submitted an application to be uplisted to NASDAQ
• The company believes listing its shares of common stock on the Nasdaq Capital Market, which is subject to approval and fulfillment of applicable requirements, will improve liquidity, increase its corporate visibility, and enhance shareholder value
• FingerMotion’s first upgrade came in February 2019, when it announced it had been uplisted and approved to trade on the OTCQB Venture Marketplace
• In January 2021, the company was again uplisted to the OTCQX, where it currently trades and will continue trading until its application to join the NASDAQ is approved

FingerMotion (OTCQX: FNGR), an evolving technology company with core competence in SMS/MMS as well as mobile payment and recharge platform solutions in China, recently announced it has applied to have its shares of common stock listed on Nasdaq Capital Market, subject to NASDAQ’s approval and fulfillment of all applicable listing, governance, and regulatory requirements (https://ibn.fm/7quFq). “Over the past year, we have been working diligently to comply with certain uplisting requirements,” said FingerMotion CEO Martin Shen. “Applying for a NASDAQ listing is a key milestone in our company’s evolution. We believe listing our common stock on the Nasdaq Capital Market will improve liquidity, increase our corporate visibility, and enhance shareholder value.” If approved, Shen noted, the uplisting will see FingerMotion join the ranks of global technology companies listed in the US. It will also mark stellar progress whose beginning, outside of the company’s establishment in 2016 and growth through the years, can be traced to February 2019 when FNGR announced it had been upgraded from pink sheets to the OTCQB Venture Marketplace. At the time, Shen intimated that the uplisting to OTCQB served as a stepping stone to meeting the listing requirements for admission on a senior exchange (https://ibn.fm/MEhSq). In January this year when FingerMotion was again upgraded to the OTCQX Best Market (https://ibn.fm/1Bye6). The upgrade marked a significant milestone for the company as it offered, and continues to do so, greater access to the capital markets. It was also an essential part of FNGR’s business plan. “The higher standards make us more transparent to institutional investors who rely on the more rigorous review of the company,” said Shen, following the uplisting to OTCQX. “The liquidity on OTCQX should also provide investors more confidence to trade our securities. The higher financial standards and reporting requirements are good for management, strategic partners, and investors as it will increase our overall appeal to attract top-level experience, partnerships, and investment.” Until its uplisting application to NASDAQ is approved, FingerMotion will continue to trade on the OTCQX under its current ticker symbol “FNGR.” The company looks forward to updating shareholders on the progress of its submission in due course. For more information, visit the company’s website at www.FingerMotion.com. NOTE TO INVESTORS: The latest news and updates relating to FNGR are available in the company’s newsroom at https://ibn.fm/FNGR

• The company will present an overview of business operations and its pipeline, including the Psilocybin-For-Neuropsychiatric Disorders (“PFN”) program for chronic pain and eating disorders
• The initial indication of lead drug candidate TRP-8802 is for fibromyalgia, but Tryp believes that psilocybin can be used for much more in the realm of unmet medical needs
• PFN’s development for its proprietary drug candidate, TRP-8803, focuses on increased efficacy, natural blood-brain barrier penetration, enhanced safety and toxicity profiles, reduced risk of abuse, and reduced risk of addiction

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a San Diego-based pharmaceuticals company, has joined the lineup of presenters at this year’s Canaccord Genuity Virtual Growth Conference, to be held virtually on August 10-12. Tryp is focused on developing psilocybin-based clinical-stage compounds for diseases with high unmet medical needs through accelerated regulatory pathways (https://ibn.fm/gxu6h). Tryp Chairman and CEO Greg McKee stated that the company would be presenting an overview of the business and its pipeline – including Tryp’s Psilocybin-For-Neuropsychiatric Disorders (“PFN”) program for chronic pain and eating disorders. Tryp’s presentation will be held on August 10 at 3 p.m. EST. Register to view the presentation at https://ibn.fm/ja8ep. Prior to this announcement, Tryp released a broadcast titled, “Psychedelics – Not Just for Mental Health Anymore,” highlighting the historical knowledge of psychedelics, such as peyote and psilocybin, and their healing effects, (https://ibn.fm/6c1sq). Modern-day research was hindered by the Controlled Substances Act of 1970, classifying psychedelics as Schedule I drugs with no medical use. In the last few years, research has been lifting this stigma, including research done by Johns Hopkins Medical showing that two doses of psilocybin in combination with psychotherapy generated reduced symptoms for adults suffering from major depression. (can we link to the trial here). Many psychedelic companies have focused on depression, but Tryp is confident that psilocybin can effectively treat other underserviced indications, including chronic pain and certain eating disorders. Tryp’s PFN program is focused on the development of psilocybin-based drug therapy for certain neuropsychiatric disorders. The psilocybin-based therapies have distinct advantages over other drugs currently on the market or in development, including:

• Increased efficacy
• Natural blood-brain barrier penetration
• Enhanced safety and toxicity profiles
• Reduced risk of abuse
• Reduced risk of addiction

PFN features Tryp’s lead drug candidate, TRP-8802, with an initial indication of fibromyalgia. Tryp plans to seek FDA approval to proceed to Phase 2a clinical trials to evaluate the drug as a treatment for fibromyalgia based on existing preclinical and clinical data for the active pharmaceutical ingredients found in TRP-8802. So far in 2021, Tryp has achieved significant milestones, which include expanding its roster of world-class scientific advisors, initiating collaborations with world-renowned research institutions to advance clinical trials, advancing the manufacturing capability for synthetic psilocybin, and more. Tryp plans to continue achieving several other milestones before the end of 2021. These milestones include initiating at least two Phase 2a trials, announcing several new clinical research collaborations with leading academic research institutions, successful manufacturing and formulation of GMP synthetic psilocybin using proprietary methods, and filing for additional intellectual property applications. For more information, visit the company’s website at www.TrypTherapeutics.com. NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF

• GPFT forms strategic alliance with 6PAK Solutions Inc
• Company working to achieve goal of launching Hourglass in Canada in the third quarter of 2021
• Grapefruit’s patented Hourglass delivery cream system has fundamentally changed the way humans absorb cannabinoids

In the United States, Grapefruit USA (OTCQB: GPFT) provides consumers with one of the most effective cannabis topical creams on the market. Now, through its partnership with 6PAK Solutions Inc., Grapefruit can offer its patented Hourglass(TM) Time Release THC+CBD Delivery Topical Relief Cream in Canada too (https://ibn.fm/ofMBY). “We are very encouraged by 6PAK’s decision to form an alliance with Grapefruit to take the initial steps toward obtaining Canadian regulatory approval to bring Grapefruit’s patented time-release THC+CBD topical delivery cream to all Canadians,” said Grapefruit CEO and cofounder Bradley J. Yourist. “6PAK Solutions’ expertise in this area is unrivaled and assures Grapefruit will bring a fully compliant cannabis product to market in Canada. 6PAK is a subsidiary of ATG Pharma, Inc., a leader in regulatory-compliant filling and packaging for the cannabis industry in Canada, so we are in good hands indeed. Our team looks forward to working with Chris Shar and his team in the coming weeks to achieve our corporate goal of introducing Hourglass across the entire nation of Canada in the third quarter of 2021.” Late last month, Grapefruit announced that it had formed a strategic alliance with 6PAK, a well-respected Canadian cannabis manufacturer and arm of ATG Pharma Inc. According to the agreement, GPFT will file a Notice of New Cannabis Product (“NNCP”) with Health Canada; the NNCP outlines the Hourglass production process including the integration of Grapefruit’s patented Z-Pod Xerogel Silica Gel technology into the Hourglass topical delivery cream system. The company hopes to receive approval of the NNCP by third quarter 2021. Once approval is received, the company will work with 6PAK to launch its exclusive Hourglass Time Release THC+CBD Delivery Topical Relief Cream in the Canadian market. “With our strong roots in the Canadian market and service-focused approach, we are proud to offer a platform for Hourglass to bring new and innovative products to the Canadian consumer,” said 6PAK cofounder Chris Shar. Grapefruit’s patented Hourglass delivery cream system is a powerful disruptive delivery technology that has fundamentally changed the way humans absorb cannabinoids such as THC and CBD. Improved absorption means improved benefits, and THC and CBD are purported to provide a host of holistic advantages. A simple application of Grapefruit’s Hourglass cream on the skin is all that is needed for users to enjoy the full-body entourage effects and related relief provided by THC and other beneficial cannabinoids. Because Grapefruit is the exclusive licensee of the Z-Pod Xerogel Silica Gel for cannabis products in North America and the only company that knows how to manufacture the Hourglass time-release delivery cream using the xerogel gel, the company can lay claim to the unique benefits the cream provides. Joining the Grapefruit team, which notes that Hourglass is the future of healthy cannabis delivery systems, are its approved retailers located throughout the United States, Canada and Mexico. Grapefruit holds California permits and licenses to both manufacture and distribute cannabis products in the Golden State. The company’s extraction laboratory and manufacturing and distribution facilities are located in the industry-recognized Coachillin’ Industrial Cultivation and Ancillary Canna-Business Park in Desert Hot Springs, located on the extension of North Canyon Road, approximately 14 miles north of downtown Palm Springs. To find out more about the company and its game-changing Hourglass time-release cannabinoid delivery cream, please visit www.GrapefruitBlvd.com. NOTE TO INVESTORS: The latest news and updates relating to GPFT are available in the company’s newsroom at https://ibn.fm/GPFT

• Company announces official approval for its common shares to be listed, traded on NYSE American
• Cybin will commit resources to reach the broadest investor audience, accelerate efforts to position Cybin as sector leader
• Companies that list on NYSE American can leverage a wide range of advantages

In an historic move, Cybin (NEO: CYBN) (NYSE American: CYBN) will become the first psychedelic biotech company to trade on the NYSE American LLC stock exchange (https://ibn.fm/LQryy). Cybin received official approval for its common shares to be listed and traded on NYSE American last week, and the company anticipates that shares will start trading on or about August 5, 2021, under the symbol CYBN. “We are all delighted to receive this approval from the NYSE American and are thankful to our wonderful team and loyal investor base who have followed us on this journey so far,” said Cybin CEO Doug Drysdale. “As the first psychedelic biotech company that will now trade on this esteemed exchange in the U.S., we will commit resources to reach the broadest investor audience with our mission and will continue to accelerate our efforts to position Cybin as a leader in the sector.” Drysdale noted that the company expected that expanded access to investors would further fuel Cybin’s mission to develop revolutionary psychedelic therapeutics for patients suffering from mental health conditions (https://ibn.fm/TssUu). Designed for growing companies, the NYSE American exchange draws on its heritage as the American Stock Exchange and offers investors greater choice in how they trade (https://ibn.fm/wOUM7). The exchange is a competitively priced venue that blends unique features derived from the NYSE, such as electronic designated market makers (e-DMMs) with quoting obligations for each NYSE American-listed company, with NYSE Arca’s fully electronic price/time priority execution model. Companies that list on the NYSE American can leverage a wide range of advantages, including access to capital, improved branding and visibility, accountability, and increased liquidity. Cybin also noted that, in addition to listing and trading on the NYSE American in U.S. dollars, Cybin’s common shares will continue to be listed and trade in Canada on the NEO Exchange in Canadian dollars, also under the symbol CYBN. Cybin Corp., a leading biotech company focused on progressing psychedelic therapeutics, is on a mission to revolutionize mental health care. The company is focused on progressing psychedelic therapeutics by utilizing proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. For more information, visit the company’s website at www.Cybin.com. NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

• Patented NeuroCap(TM) and NeuroEEG(TM) devices can be used anywhere, ideal for clinical research labs, neurology clinics, urgent care clinics, emergency departments, ICUs, assisted living facilities, and nursing homes
• Current global market for EEG devices estimated at $956.1 million in 2020, expected to reach $1.6 billion revenue by 2026, CAGR of 8.7% between 2019-2026

Brain Scientific (OTCQB: BRSF), a commercial-stage healthcare company, focuses on developing cost-effective next-generation medical devices and software with the goal of modernizing and increasing accessibility to brain diagnostics for the rapidly growing neurology market. Brain Scientific’s patented NeuroCap(TM) and NeuroEEG(TM) devices are positioned to disrupt the expensive EEG market. Company’s Neurotech ecosystem consists of devices that are affordable and sustainable FDA cleared alternatives to the EEG technology seen today. Devices can be used in a wide range of settings, including remote clinical research labs, neurology clinics, urgent care clinics, emergency departments, ICUs, assisted living facilities, and nursing homes. The NeuroCap – an FDA-cleared disposable pre-gelled EEG headset – features 22 electrodes and 19 active EEG channels that can be used for recording EEGs in nearly any setting. It is complemented by the NeuroEEG, an FDA-cleared portable clinical-grade wireless EEG amplifier that acquires, records, displays and transmits electrical brain activity. In the future company’s technology will leverage AI and ML technology with an extensive database comprised of normal and abnormal brain data to help detect abnormal activity associated with brain-related diseases like epilepsy, dementia and pre-Alzheimer’s disease. With a cloud-based infrastructure, the devices will be able to collect, aggregate and analyze data, resulting in the rapid development of algorithms that can accurately detect neurological disorders. The company’s three-stage development process commenced with the first phase in 2018 that resulted in the creation of the NeuroCap and NeuroEEG. The second phase – currently ongoing – is focused on the development of essential cloud-based infrastructure that will be used to transmit data between patients and neurologists. The third and final phase, scheduled for later this year and into 2022 and 2023, will focus on the development of AI and ML processes to increase efficiency, consistency, and accuracy of diagnostic analytics provided by the application. According to Grandview Research, the current global EEG device market was estimated at $956.1 million in 2020 and is expected to reach $1.6 billion revenue by 2026 with an expected CAGR of 8.7% between 2019-2026 (https://ibn.fm/HYehK). Currently, over 150 million people are diagnosed globally with epilepsy, dementia and Alzheimer’s disease, and BRSF management expects the market for neurodiagnostic devices to expand in tandem with the growth of neurological disorders throughout the world (https://ibn.fm/a0AEW). Brain Scientific Inc. aims to address this target market by providing next-generation EEG devices that will leverage AI and ML technology to facilitate the early diagnosis of brain disorders. With a rock-solid commercialization strategy and diverse management team of experts, Brain Scientific is positioned to lead the market in cost-effective portable EEG devices that enable medical professionals to diagnose patients with efficiency, consistency and accuracy in virtually any setting. For more information, visit the company’s website at www.BrainScientific.com/Invest-Now. NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

• Company enters into MOU to acquire auto import/export company
• Opportunities are to maintain excellence, leverage channels to grow sales
• DSG anticipates seeing impressive results soon after closing, plans to increase cash flow with positive revenue

In a move that provides immediate sales opportunities, DSG Global (OTCQB: DSGT) announced that it has entered into a binding memorandum of understanding to acquire MTG Inc., an established automotive import/export company based in Ontario (https://ibn.fm/gZE00). MTG operates in Canada, the United States and Mexico and has extensive commercial fleet and retail connections throughout the global automotive industry. “We are acquiring a proven entity and the talent that built it,” stated DSG Global CEO Bob Silzer. “MTG and [Johnny] Cooper’s previous company have completed well over a billion dollars in sales. The opportunities before us are to maintain the excellent company they have built and leverage their sales and distribution channels for growing our electric vehicle sales more expediently.” According to the company, the transaction should be complete sometime in third quarter 2021, subject to several conditions. Once the acquisition is finalized, MTG’s customer base and multimillion-dollar monthly sales will be integrated into a new division — DSG Wholesale Division — led by renowned automotive specialists Michael Tersigni and Johnny Cooper. Cooper has invaluable experience with this business model, having created a company in the late 1990s that completed transactions for more than 12,000 vehicles totaling up to $321 million in sales annually; that company was sold to one of the largest auto auction groups in the world. The company noted that the MTG acquisition allows it to immediately expand cross-border sales for both new and late-model vehicles; the strategic move will afford MTG’s current and future fleet and consumer channels strong trade-in values on electric vehicles purchased from Imperium, along with a large dealer base creating sales for Imperium Motors. DSG anticipates the division will see impressive results soon after closing and plans to increase cash flow with positive revenue as well as enhance its own EV business by offering a unique buying experience to Imperium clients. DSGW will be one of the only OEM EV companies offering to take used inventory and dispose of the units, making it the go-to full-service provider of world-class EV products for fleet and consumer transportation. The strategic timing of this move is ideal for the company. “Every business proposition boils down to when, how and how much,” said Silzer. “Well, when is now, in that we have SUVs, trucks, sedans and other vehicles either in port or arriving soon. How we are getting product to market is explained via this acquisition and the dealers with whom we will work. Both our manufacturing partners have no issues obtaining critical computer chips, therefore no delivery delays, as several manufacturers have experienced. And the how much could have been a relevant question if we had not purchased MTG to be a wholesale distribution network. “Because of this opportunity, we are really only left with the all-important question of how much the Imperium brands will cost consumers,” Silzer concluded. “The answer is, surprisingly less than many other EVs. For example, the ET5 SUV comes extremely well-equipped at around $40,000 less available incentives and tax credits in most cases.” DSG Global is an emerging global technology company with an array of interconnecting businesses in some of the fastest-growing market sectors. With roots in the golf industry, in which it specializes in fleet management with patented analytics, mobile touch-screen engagement and electric golf carts under the Vantage Tag Systems (“VTS”) brand, the company is moving quickly with road-ready electric vehicles for sale in the third quarter of 2021 through its Imperium Motor Company subsidiary. For more information, visit the company’s website www.DSGTGlobal.com. NOTE TO INVESTORS: The latest news and updates relating to DSGT are available in the company’s newsroom at https://ibn.fm/DSGT

Online Livestreaming Event Date: August 16-17, 2021 Clinical researchers, medical managers, pharma companies, and life science professionals are invited to attend the 2nd Electronic Trial Master File (“eTMF”) Forum on August 16-17th, 2021. This 2-day event will offer a leading stage to learn the skills of integrated TMF technology for successful clinical research. Attendees will understand the intricacies of identifying the challenges and risks posed during clinical research. They will learn to identify how to protect the data gathered during the research trials, meeting regulatory requirements, preparing for audits, getting ready for inspections, and lucrative techniques for monitoring and filing correspondence. The event is powered by the Scaritt Group, Inc. and the TMF Professionals. The 2nd eTMF Forum is hosted by Dynamic Global Events (“DGE”), a Life Science Leader in organizing B2B Events. The Global Event Company caters to the dynamic informational and networking needs of the Pharmaceutical, Biotechnology, Healthcare, Medical Devices, and allied industries. The 2nd Electronic Trial Master File Forum is an online live streaming event that will witness the leading industry stalwarts from around the globe sharing their opinion, views and perspective about seamlessly conducting clinical trial research. Some important elements of the event’s agenda include:

• Stay ahead in competition through advanced inspection readiness solutions
• Data privacy risks and challenges for intellectual property
• Improving collaboration techniques between CROs and sites
• Ensure a secure quality monitoring and quality-control procedure
• Communicate the expectation of the completion time of a completeness review
• Communicate the work instructions among the sponsors and third parties and align with SOPs

The 2nd Electronic Trial Master File Forum is of special interest to Solution Providers, Paper and Electronic Archiving systems, Clinical Research Organizations, Data Records Managers, and eTMF Service Providers, who will get an overview of pre and post-inspection readiness and recognize the importance of timing and readability. They will further learn the use of technology for maximum integration and explore completeness review from a resourcing and staffing perspective. Speakers at the event will discuss how an inspection ready TMF requires a comprehensive approach, accounting for variables, and sound evaluation of parameters that could go wrong. Refining collaborative processes with CROs and understanding their requirements and motivations are some of the key lessons that will be discussed at the Forum. To know more about the event, please visit https://ibn.fm/9Qfkt

• Pet CBD industry projected to reach $1.7 billion by 2025
• GPFT’s new pet CBD product targets two common dog, cat ailments: anxiety and joint pain
• Pets deserve the same relief that their owners experience with Grapefruit’s CBD products, says CEO

Humans aren’t the only ones who may benefit from all that cannabidiol (“CBD”) offers. A recent Brightfield Group article reported that the pet CBD industry has experienced significant growth over the last several years, with Brightfield projecting an expected market valuation of more than $1.7 billion by 2025 (https://ibn.fm/jbMU2). Grapefruit USA (OTCQB: GPFT) is leveraging its expertise in the space by launching a new USDA-certified Organic CBD Pet Tincture. “We understand that pet owners are now demanding organic, plant-based, natural remedies to keep their furry family members calm and in good health, and avoid the potential negative side effects of generic, synthetic pet medications,” said Bradley Yourist, cofounder and CEO of GPFT. “Grapefruit’s new Pet CBD Tincture meets this pet-owner market demand because it is derived from hemp grown right here in the U.S., and each batch is lab tested for purity.” A premiere, fully licensed, California-based cannabis company, Grapefruit is expanding its hemp-based CBD product line with the new pet tincture, which targets two of the most common dog and cat ailments: anxiety and joint pain. Grapefruit’s new Pet 300 mg CBD hemp-based tincture is derived from USDA-certified organic hemp, grown in the United States. “Our commitment to obtain the USDA-certified organic seal clearly demonstrates GPFT’s continued commitment to creating the best high-quality, safe and effective CBD products for our customers, be they human, feline, canine or otherwise,” Yourist continued. “Our pets deserve the same relief that their owners have experienced with our other CBD products, such as our THC-free, hemp-derived CBD Hourglass time-release topical relief cream.” Grapefruit noted that overall pet ownership is increasing, partly due to the pandemic, with more than half of all U.S. households having a furry family member. In addition, research shows that more than 64% of CBD consumers buy CBD products for their pets because of the holistic benefits they provide. The global CBD pet market size was valued at $27.7 million in 2019 and is expected to grow at a compound annual growth rate (“CAGR”) of 40.3% from 2020 to 2027. With its expertise in the CBD space, Grapefrult is ideally positioned to be a strong presence in this market. Grapefruit holds California permits and licenses to both manufacture and distribute cannabis products in the Golden State. The company’s extraction laboratory and manufacturing and distribution facilities are located in the industry-recognized Coachillin’ Industrial Cultivation and Ancillary Canna-Business Park in Desert Hot Springs, located on the extension of North Canyon Road, approximately 14 miles north of downtown Palm Springs. To find out more about the company and its game-changing Hourglass time-release cannabinoid delivery cream, please visit www.GrapefruitBlvd.com. NOTE TO INVESTORS: The latest news and updates relating to GPFT are available in the company’s newsroom at https://ibn.fm/GPFT